Careers  |  Sign In  |  Register  |   Twitter

Latest in Hematology-Oncology

Bloomberg News reports that doctors at Duke University Hospital performed the first genetically engineered blood vessel implantation in the U.S. on a 62-year-old man suffering from kidney failure. The vessel was placed in the patient’s arm so that it could easily be used in the future for dialysis....

Reuters Health • The Doctor's Channel Daily Newscast

Targeted Immunotoxin Highly Active Against Advanced Acute Lymphocytic Leukemia

NEW YORK (Reuters Health) – Over half of patients with refractory and relapsed acute lymphocytic leukemia (ALL) achieve a complete or partial response when treated with the CD22 monoclonal antibody agent, inotuzumab ozogamicin. This agent and other monoclonal antibodies “potentially offer the first...

Reuters Health • The Doctor's Channel Daily Newscast

High Response Rate to Seq. Chemoimmunotherapy for T-cell Prolymphocytic Leukemia

NEW YORK (Reuters Health) – A European study indicates that patients with T-cell prolymphocytic leukemia may respond well to induction chemotherapy using fludarabine, mitoxantrone and cyclophosphamide, followed by consolidation with alemtuzumab. However, despite a high overall response rate, the...